Meta-analytic microbiome target discovery for immune checkpoint inhibitor response in advanced melanoma

Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment, yet patient responses remain highly variable, underscoring the need for predictive biomarkers. Emerging evidence suggests that gut microbiome composition influences ICI efficacy, though findings remain inconsistent across studies. Here, we present a meta-analysis of seven melanoma-associated microbiome cohorts (N=678) using a standardized computational pipeline to integrate microbial species, biosynthetic gene clusters (BGCs), and functional pathways. We identify Faecalibacterium SGB15346 as a key species enriched in responders, alongside RiPP biosynthetic class and pathways involved in short-chain fatty acid fermentation. Conversely, dTDP-sugar biosynthesis correlates with non-response. Our results highlight microbial signatures and metabolic pathways associated with ICI outcomes, offering potential targets for microbiome-based interventions in personalized immunotherapy.